GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Applied DNA Sciences Inc (NAS:APDN) » Definitions » Free Cash Flow

APDN (Applied DNA Sciences) Free Cash Flow : $-13.14 Mil (TTM As of Jun. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Applied DNA Sciences Free Cash Flow?

Applied DNA Sciences's total free cash flow for the months ended in Jun. 2024 was $-3.50 Mil. Its total free cash flow for the trailing twelve months (TTM) ended in Jun. 2024 was $-13.14 Mil.

Applied DNA Sciences's Free Cash Flow per Share for the months ended in Jun. 2024 was $-0.87. Its free cash flow per share for the trailing twelve months (TTM) ended in Jun. 2024 was $-14.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 45.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Free Cash Flow Growth Rate using Free Cash Flow per Share data.

During the past 13 years, Applied DNA Sciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 56.80% per year. The lowest was -11.50% per year. And the median was 21.00% per year.


Applied DNA Sciences Free Cash Flow Historical Data

The historical data trend for Applied DNA Sciences's Free Cash Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Applied DNA Sciences Free Cash Flow Chart

Applied DNA Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Free Cash Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.93 -12.21 -15.94 -9.47 -6.30

Applied DNA Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Free Cash Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -2.68 -3.76 -3.21 -3.50

Applied DNA Sciences Free Cash Flow Calculation

Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company.

Applied DNA Sciences's Free Cash Flow for the fiscal year that ended in Sep. 2023 is calculated as

Free Cash Flow (A: Sep. 2023 )=Cash Flow from Operations+Capital Expenditure
=-6.218+-0.078
=-6.30

Applied DNA Sciences's Free Cash Flow for the quarter that ended in Jun. 2024 is calculated as

Free Cash Flow (Q: Jun. 2024 )=Cash Flow from Operations+Capital Expenditure
=-3.495+0
=-3.50

Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Applied DNA Sciences  (NAS:APDN) Free Cash Flow Explanation

Free Cash Flow is very close to Warren Buffett's definition of Owner's Earnings, except that in Warren Buffett's Owner's Earnings, the spending for Property, Plant, and Equipment is only for maintenance (replacement), while in the Free Cash Flow calculation, the cost of new Property, Plant, and Equipment due to business expansion is also deducted. There, Free Cash Flow is more conservative than Owner's Earnings.

In Don Yacktman's calculation of forward rate of return, he uses Free Cash Flow for the calculation. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation.

This is what Yacktman said in his March 2012 interview - when the S&P 500 was at 1400:

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over seven years. The reason we use seven years is because research shows that seven years is the length of the typical business cycle.

Therefore, as of Jun24, Applied DNA Sciences's Forward Rate of Return (Yacktman) % is

Forward Rate of Return (Yacktman) % (Jun24)=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.4084+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Free Cash Flow within a report period can be affected by management's decisions of capital spending. Therefore, it is important to look at long term when it comes to Free Cash Flow.


Applied DNA Sciences Free Cash Flow Related Terms

Thank you for viewing the detailed overview of Applied DNA Sciences's Free Cash Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Applied DNA Sciences Business Description

Traded in Other Exchanges
N/A
Address
50 Health Sciences Drive, Stony Brook, New York, NY, USA, 11790
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) nd ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Executives
Clay Shorrock officer: Chief Legal Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Scott L Anchin director 16990 GOLDENTOP ROAD, SUITE A, SAN DIEGO CA 92127
William W Montgomery 10 percent owner 34211 SEAVEY LOOP RD., EUGENE OR 97405
Judith Murrah officer: Chief Information Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Beth Jantzen officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov A Shamash director
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
John Iii Bitzer director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Joseph D. Ceccoli director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Elizabeth M. Ferguson director 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Charles S. Ryan director C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
James A Hayward director, officer: Chief Executive Officer C/O 25 HEALTH SCIENCES DRIVE, SUITE 113, NEW YORK NY 11790
Karol Gray officer: Chief Financial Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Ming-hwa Benjamin Liang officer: Strategic Tech. Dev. Officer C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Yacov Shamash director 100 ENGINEERING, STATE UNIVERSITY OF NY, STONE BROOK NY 117942200

Applied DNA Sciences Headlines

From GuruFocus